Get the Stockscreener App
6.16
5.38%
-0.35
Nuvectis Pharma Inc stock is traded at $6.16, with a volume of 76,495.
It is down -5.38% in the last 24 hours and down -9.68% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$6.51
Open:
$6.45
24h Volume:
76,495
Relative Volume:
0.58
Market Cap:
$156.81M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-4.3688
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
-7.78%
1M Performance:
-9.68%
6M Performance:
-20.41%
1Y Performance:
-5.23%
1-Day Range:
$6.15
$6.4661
1-Week Range:
$6.15
$6.88
52-Week Range:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.16 | 159.87M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Full technical analysis of Nuvectis Pharma Inc. stockExit Point & AI Powered Buy/Sell Recommendations - Newser
Custom watchlist performance reports with Nuvectis Pharma Inc.July 2025 Market Mood & Scalable Portfolio Growth Ideas - Newser
How high can Nuvectis Pharma Inc. stock goJuly 2025 Macro Moves & Capital Protection Trading Alerts - Newser
Best data tools to analyze Nuvectis Pharma Inc. stockQuarterly Earnings Summary & Community Consensus Stock Picks - Newser
Smart tools for monitoring Nuvectis Pharma Inc.’s price actionJuly 2025 Movers & Smart Allocation Stock Reports - Newser
Should you wait for a breakout in Nuvectis Pharma Inc.2025 Pullback Review & Fast Entry High Yield Stock Tips - Newser
Why Nuvectis Pharma Inc. is moving todayMarket Sentiment Report & Real-Time Volume Analysis - Newser
Nuvectis Pharma Inc.’s volatility index tracking explainedWeekly Profit Analysis & Weekly High Return Forecasts - Newser
Will breakout in Nuvectis Pharma Inc. lead to full recoveryEarnings Beat & Technical Buy Zone Confirmation - Newser
How to escape a deep drawdown in Nuvectis Pharma Inc.2025 Short Interest & Community Trade Idea Sharing - Newser
What to expect from Nuvectis Pharma Inc. in the next 30 days2025 Trade Ideas & High Conviction Investment Ideas - Newser
Can technical indicators confirm Nuvectis Pharma Inc.’s reversalMarket Weekly Review & Verified Swing Trading Watchlist - Newser
How to recover losses in Nuvectis Pharma Inc. stock2025 Price Action Summary & AI Based Trade Execution Alerts - Newser
Nuvectis Pharma Inc. stock trend outlook and recovery pathMarket Trend Report & Safe Capital Growth Tips - Newser
Combining machine learning predictions for Nuvectis Pharma Inc.Weekly Profit Recap & Verified Momentum Watchlists - Newser
Is Nuvectis Pharma Inc. stock ready for a breakoutEarnings Summary Report & Detailed Earnings Play Alerts - Newser
What recovery options are there for Nuvectis Pharma Inc.Quarterly Performance Summary & Expert-Curated Trade Recommendations - Newser
Tools to monitor Nuvectis Pharma Inc. recovery probability2025 Earnings Impact & Free Technical Pattern Based Buy Signals - Newser
Analyzing Nuvectis Pharma Inc. with multi timeframe chartsEarnings Trend Report & Verified Entry Point Signals - Newser
Nuvectis Pharma Inc. stock chart pattern explainedPortfolio Value Summary & Weekly Watchlist of Top Performers - Newser
What earnings revisions data tells us about Nuvectis Pharma Inc.Quarterly Investment Review & Reliable Breakout Forecasts - Newser
Nuvectis Pharma Inc. recovery potential after sell off2025 Earnings Surprises & Safe Swing Trade Setup Alerts - Newser
Using AI based signals to follow Nuvectis Pharma Inc.Weekly Investment Summary & AI Powered Trade Plan Recommendations - Newser
Is Nuvectis Pharma Inc. still worth holding after the dipJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser
What Fibonacci levels say about Nuvectis Pharma Inc. reboundPortfolio Performance Report & Weekly Breakout Stock Alerts - Newser
What MACD signals say about Nuvectis Pharma Inc.Trend Reversal & Daily Momentum Trading Reports - Newser
Is Nuvectis Pharma Inc. stock entering bullish territoryMarket Growth Review & Low Drawdown Investment Ideas - Newser
Price action breakdown for Nuvectis Pharma Inc.Market Activity Summary & Consistent Profit Focused Trading Strategies - Newser
Exit strategy if you’re trapped in Nuvectis Pharma Inc.Earnings Growth Summary & Daily Technical Forecast Reports - Newser
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):